{
    "id": 25152,
    "fullName": "TPR - MET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TPR-MET results from the fusion of TPR and MET, which leads to constitutive activation of kinase activity resulting in cell transformation in culture (PMID: 7838524).",
            "references": [
                {
                    "id": 6460,
                    "pubMedId": 7838524,
                    "title": "Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/7838524"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7175,
        "geneSymbol": "TPR",
        "terms": [
            "TPR"
        ]
    },
    "variant": "TPR - MET",
    "createDate": "08/11/2016",
    "updateDate": "08/11/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4233,
                "geneSymbol": "MET",
                "terms": [
                    "MET",
                    "AUTS9",
                    "c-Met",
                    "DFNB97",
                    "HGFR",
                    "RCCP2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET were resistant to Tivantinib (ARQ197) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET demonstrated decreased response to Cometriq (Cabometyx, cabozantinib) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9522,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET demonstrated sensitivity to Cometriq (Cabometyx, cabozantinib) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited survival of osteosarcoma cells harboring TPR-MET in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing TPR-MET in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing TPR-MET in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 inhibited Met signaling and proliferation of transformed cells over expressing TPR-MET in culture (PMID: 26483207).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 916,
                "therapyName": "SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET demonstrated decreased response to Xalkori (crizotinib) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited tumor growth in mouse tumor models expressing TPR-MET (PMID: 27196782).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BVU972 inhibited Met phosphorylation and growth of transformed cells expressing TPR-MET in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing TPR-MET in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing TPR-MET in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET demonstrated sensitivity to Savolitinib (AZD6094) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13581,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET were sensitive to SCC244 treatment, demonstrating decreased Met activity and downstream signaling and inhibition of cell proliferation in culture (PMID: 29237805).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET demonstrated decreased response to Glesatinib (MGCD265) compared to cells expressing sensitizing MET mutations in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9524,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET and MET D1228V demonstrated sensitivity to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26884,
                "profileName": "TPR - MET MET D1228V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9523,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPR-MET and MET D1228V demonstrated resistance to Savolitinib (AZD6094) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26884,
                "profileName": "TPR - MET MET D1228V"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9527,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated sensitivity to the combination of Iressa (gefitinib) and Savolitinib (AZD6094) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 5063,
                "therapyName": "Gefitinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9525,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9528,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated sensitivity to the combination of Iressa (gefitinib) and Cometriq (Cabometyx, cabozantinib) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 5064,
                "therapyName": "Cabozantinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9526,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9530,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated resistance to the combination of Iressa (gefitinib) and Savolitinib (AZD6094) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 5063,
                "therapyName": "Gefitinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9529,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated sensitivity to the combination of Iressa (gefitinib) and Cometriq (Cabometyx, cabozantinib) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 5064,
                "therapyName": "Cabozantinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21110,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing a TPR-MET fusion bearing MET Y1230H demonstrated resistance to Capmatinib (INC280) treatment in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27244,
                "profileName": "TPR - MET MET Y1230H"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10099,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET Y1230H demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27244,
                "profileName": "TPR - MET MET Y1230H"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10108,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 458 inhibited Met phosphorylation and growth of transformed cells expressing a TPR-MET fusion harboring MET Y1230H (PMID: 21697284).",
            "molecularProfile": {
                "id": 27244,
                "profileName": "TPR - MET MET Y1230H"
            },
            "therapy": {
                "id": 2163,
                "therapyName": "AMG 458",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET D1228H demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27246,
                "profileName": "TPR - MET MET D1228A"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing a TPR-MET fusion bearing MET D1228A demonstrated resistance to Capmatinib (INC280) treatment in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27246,
                "profileName": "TPR - MET MET D1228A"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10112,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 458 inhibited Met phosphorylation and growth of transformed cells expressing a TPR-MET fusion harboring MET D1228A in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27246,
                "profileName": "TPR - MET MET D1228A"
            },
            "therapy": {
                "id": 2163,
                "therapyName": "AMG 458",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited proliferation of a transformed human cell line expressing a TPR-MET fusion bearing MET V1155L in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27248,
                "profileName": "TPR - MET MET V1155L"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET V1155L demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27248,
                "profileName": "TPR - MET MET V1155L"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21108,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited proliferation of a transformed human cell line expressing a TPR-MET fusion bearing MET L1195V in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27249,
                "profileName": "TPR - MET MET L1195V"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10115,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET L1195V demonstrated a decreased response to inhibition by AMG 458 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27249,
                "profileName": "TPR - MET MET L1195V"
            },
            "therapy": {
                "id": 2163,
                "therapyName": "AMG 458",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10105,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET L1195V demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27249,
                "profileName": "TPR - MET MET L1195V"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10114,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET F1200I demonstrated a decreased response to inhibition by AMG 458 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27253,
                "profileName": "TPR - MET MET F1200I"
            },
            "therapy": {
                "id": 2163,
                "therapyName": "AMG 458",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10102,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a TPR-MET fusion harboring MET F1200I demonstrated resistance to inhibition by NVP-BVU972 in culture (PMID: 21697284).",
            "molecularProfile": {
                "id": 27253,
                "profileName": "TPR - MET MET F1200I"
            },
            "therapy": {
                "id": 5378,
                "therapyName": "NVP-BVU972",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8018,
                    "pubMedId": 21697284,
                    "title": "A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21697284"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21107,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited proliferation of a transformed human cell line expressing a TPR-MET fusion bearing MET F1200I in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 27253,
                "profileName": "TPR - MET MET F1200I"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25934,
            "profileName": "TPR - MET",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26884,
            "profileName": "TPR - MET MET D1228V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26885,
            "profileName": "TPR - MET EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26886,
            "profileName": "TPR - MET MET D1228V EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27244,
            "profileName": "TPR - MET MET Y1230H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27246,
            "profileName": "TPR - MET MET D1228A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27248,
            "profileName": "TPR - MET MET V1155L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27249,
            "profileName": "TPR - MET MET L1195V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27253,
            "profileName": "TPR - MET MET F1200I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}